Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
S PizzamiglioC M CiniselliE de AzambujaD Agbor-TarhA Moreno-AspitiaT M SuterA TramaM C De SantisL De CeccoM V IorioM SilvestriG PruneriPaolo VerderioS Di CosimoPublished in: Breast cancer research and treatment (2024)
This study provides proof of concept that circulating microRNAs tested soon after treatment start could serve as biomarkers of cardiotoxicity in a very early stage in breast cancer patients receiving anti-HER2 therapy.
Keyphrases
- early stage
- positive breast cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- left ventricular
- heart failure
- mesenchymal stem cells
- radiation therapy
- atrial fibrillation
- cell therapy
- patient reported
- smoking cessation
- rectal cancer
- locally advanced